CUSIP 31447P100 · who reports it, how much, and how much it matters to them
13 of the 720 hedge fund managers we track reported shares of Fennec Pharmaceuticals Inc. (Nasdaq: FENC) on Form 13F for 30 June 2026. Between them they reported USD 25m. The largest position belongs to Awm Investment Company, at USD 12m. The manager with the most riding on it is Lion Point Capital, where it is 5.8% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Awm Investment Company6 funds on PPLI.com | USD 12m | 1.1% |
| 2 | Prospect Capital Advisors2 funds on PPLI.com | USD 5.4m | 2.4% |
| 3 | Marshall Wace LLP84 funds on PPLI.com | USD 1.5m | 0.0% |
| 4 | Renaissance Technologies13 funds on PPLI.com | USD 1.4m | 0.0% |
| 5 | Lion Point Capital1 fund on PPLI.com | USD 1.2m | 5.8% |
| 6 | Citadel Advisors32 funds on PPLI.com | USD 764,000 | 0.0% |
| 7 | Two Sigma Investments35 funds on PPLI.com | USD 649,000 | 0.0% |
| 8 | POINT72 Asset Management17 funds on PPLI.com | USD 606,000 | 0.0% |
| 9 | Squarepoint Ops7 funds on PPLI.com | USD 335,000 | 0.0% |
| 10 | Prelude Capital Management9 funds on PPLI.com | USD 318,000 | 0.0% |
| 11 | Millennium Management6 funds on PPLI.com | USD 283,000 | 0.0% |
| 12 | Brevan Howard Capital Management39 funds on PPLI.com | USD 231,000 | 0.0% |
| 13 | Engineers Gate Manager1 fund on PPLI.com | USD 192,000 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Lion Point Capital | USD 1.2m | 5.8% |
| 2 | Prospect Capital Advisors | USD 5.4m | 2.4% |
| 3 | Awm Investment Company | USD 12m | 1.1% |
| 4 | Prelude Capital Management | USD 318,000 | 0.0% |
| 5 | Renaissance Technologies | USD 1.4m | 0.0% |
| 6 | Brevan Howard Capital Management | USD 231,000 | 0.0% |
| 7 | Engineers Gate Manager | USD 192,000 | 0.0% |
| 8 | Marshall Wace LLP | USD 1.5m | 0.0% |
| 9 | POINT72 Asset Management | USD 606,000 | 0.0% |
| 10 | Citadel Advisors | USD 764,000 | 0.0% |
Fennec Pharmaceuticals Inc. trades under the symbol FENC on the Nasdaq. Its CUSIP, the code used on Form 13F, is 31447P100.
13 of the 720 hedge fund managers PPLI.com tracks reported Fennec Pharmaceuticals Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Awm Investment Company (USD 12m), Prospect Capital Advisors (USD 5.4m), Marshall Wace LLP (USD 1.5m), Renaissance Technologies (USD 1.4m) and Lion Point Capital (USD 1.2m).
13 managers in our coverage reported it, and between them they run 252 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Lion Point Capital, where the position was 5.8% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Fennec Pharmaceuticals Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.